NCT07299890 2025-12-23
An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07191977 2025-09-25
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
West China Hospital
Phase 2 Not yet recruiting
NCT07061717 2025-07-11
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT06810492 2025-03-17
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Phase NA Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06338644 2024-03-29
Palbociclib
Helwan University
Not yet recruiting
NCT06076772 2023-10-11
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
Assiut University
Not yet recruiting
NCT05067530 2021-10-05
CAREGIVER
Medical University of Gdansk
Phase 2 Not yet recruiting
NCT04605562 2021-09-05
Umbrella Biomarker-Guided Therapy in NPC
Sun Yat-sen University
Phase 2 Not yet recruiting